<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449462</url>
  </required_header>
  <id_info>
    <org_study_id>NL15420.081.06</org_study_id>
    <nct_id>NCT00449462</nct_id>
  </id_info>
  <brief_title>Effect of Conjugated Linoleic Acid Intake on Liver and Kidney Function</brief_title>
  <official_title>The Effect of Conjugated Linoleic Acid Intake on Liver and Kidney Function in Healthy Volunteers (CLAxon-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University of Amsterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The knowledge of the health effects of CLA on the human body is limited. However, CLA
      supplements are sold over the counter in several countries and various techniques are used to
      increase the content of CLA in food.

      The CLAxon-study will be performed to investigate wether high doses of CLA can be safely
      given to healthy human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each volunteer receives CLA enriched products for a total of 3 weeks containing approximately
      20g CLA per day. A control group is not needed. If three subjects or more show one or more
      blood values for liver and kidney function above predefined limits the study will be
      terminated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALAT</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>ASAT</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>amylase</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>bilirubin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>gamma-glutamyltranspeptidase</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>lactate dehydrogenase</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>creatinine clearance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>total cholesterol</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fatty acids</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>consumption of CLA enriched food</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-60 years

          -  serum total cholesterol &lt; 8.0 mmol/L

          -  serum triglycerides &lt; 3.0 mmol/L

          -  ALAT &lt; 45 IU/L

          -  ASAT &lt; 41 IU/L

          -  amylase 35-130 U/L

          -  alkaline phosphatase 40-125 U/L

          -  bilirubin &lt; 17 Âµmol/L

          -  gamma-glutamyltranspeptidase &gt; 75 U/L (men) and &lt; 40 U/L (women)

          -  lactate dehydrogenase 230-485 U/L

          -  creatinine clearance &gt;= 90 mL/min

          -  fasting glucose levels 70-115 mg/dL

          -  fasting insulin levels 5-30 mU/L

        Exclusion Criteria:

          -  use of cholesterol lowering medication

          -  high alcohol intake

          -  BMI &gt; 30

          -  chronic diseases (such as diabetes, cardiovascular disease, kidney and liver
             dysfunction)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingeborg A Brouwer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martijn B Katan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University of Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Amsterdam, Institute for Health Sciences</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>July 5, 2007</last_update_submitted>
  <last_update_submitted_qc>July 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2007</last_update_posted>
  <keyword>CLA</keyword>
  <keyword>liver</keyword>
  <keyword>kidney</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

